Abstract An important way in which medical research can translate into improved health outcomes is by motivating or influencing clinical trials that eventually lead to changes in clinical practice. Citations from clinical trials records to academic research may therefore serve as an early warning of the likely future influence of the cited articles. This paper partially assesses this hypothesis by testing whether prior articles referenced in ClinicalTrials.gov records are more highly cited than average for the publishing journal. The results from four high profile general medical journals support the hypothesis, although there may not be a cause-and effect relationship. Nevertheless, it is reasonable for researchers to use citations to their work from clinical trials records as evidence of the possible long-term impact of their research.
Introduction
Medical research has the ultimate goal of improving health in society (e.g., http://www. mrc.ac.uk/about/) but it is rarely possible to demonstrate the direct benefits of individual studies due to the long gestation period before related treatments or interventions are approved for patients (e.g., Drolet and Lorenzi 2011; for a scientometric approach see: Jones and Hanney 2016) . Thus, it has become common to evaluate medical researchers both formally and informally with the aid of proxy indicators, such as the prestige or impact factors of the journals in which they publish, counts of citations to their articles, or their successful funding bids. A partial exception is the case study component of the UK Research Excellence Framework (REF) (http://impact.ref.ac.uk/CaseStudies/). The two citation based methods may undervalue research that is the most directly beneficial because health outcomes do not in themselves produce journal citations. Whilst basic research is important and can lead to long term social benefits (e.g., Smith et al. 2013) , methods are needed to test for and, if necessary correct for, the apparent tendency for citation-based indicators to undervalue more applied medical research (e.g., Lewison and Dawson 1998) . One such indicator is the post-publication peer review scores given to biomedical articles by F1000 (Mohammadi and Thelwall 2013) . Moreover, citations can help to evaluate medical funders (Boyack and Jordan 2011) and alternative metrics may help with this . Similar motivations have underpinned many attempts to develop altmetrics and other alternative indicators to reflect the different valid impacts generated by academics in many disciplines (Kousha and Thelwall 2015b; Thelwall and Delgado 2015; Wilsdon et al. 2015) .
The need for an indicator of the extent to which research informs health practice can be partially addressed by counting citations from medical guidelines (Drew et al. 2016; Grant et al. 2000; Thelwall and Maflahi 2016; for patents, see: Chiou et al. 2016; Kousha and Thelwall 2015a) . Nevertheless, it can take decades for medical research to translate into proven and safe health policies or medications and so citations from guidelines are unlikely to reflect recent research. Guideline citations may also tend to cite research that proves the efficacy or safety of a treatment rather than the primary research that invented the treatment or that initially demonstrated its promise. Citations from clinical trials records may fill both of these gaps by being substantially quicker and more likely to cite key innovations. There are now regulations mandating the public registration of clinical trials in some countries, such as the USA, where the responsible parties must register them in ClinicalTrials.gov prior to starting (Tse et al. 2009 ) and report results in a timely fashion (Prayle et al. 2012) . Moreover, some journals require published studies to have been pre-registered in an appropriate site (Laine et al. 2007; Palma and Zietman 2015) . ClinicalTrials.gov contains information about a large number of public and commercial trials (Califf et al. 2012; Hirsch et al. 2013; Ross et al. 2009; Stockmann et al. 2014; Zarin et al. 2005 Zarin et al. , 2011 ) and so it is now possible to count citations from clinical trials records. These citations can therefore be evaluated as a new source of evidence about the health benefits promise of medical research. Even though few trials based on published ideas lead to new treatments (Contopoulos-Ioannidis et al. 2003) , the mere existence of a trial based on a publication suggests the potential practical value of the new ideas, if even fewer basic research findings lead to beneficial medical outcomes (e.g., Ioannidis 2006) . Nevertheless, the requirement for responsible parties to register clinical trials publicly is not internationally universal and there is no requirement to cite relevant prior work systematically. Hence, it is not clear whether there will be enough citations from clinical trials documents to be worth counting. It is also not clear whether citations from clinical trials are effectively random, biased or dominated by self-citations.
This article introduces a method to count citations from clinical trials and assesses whether they are likely to be useful as impact evidence. In order to investigate the value of clinical trials citations, articles in four high profile general medical journals were compared based upon whether they had been referenced in ClinicalTrials.gov records. It is important to compare articles from the same journal because the prestige of a journal can affect the number of times that an article is cited (Larivière and Gingras 2010) and journals have different disciplinary foci, leading to different natural citation rates for their articles (Seglen 1997) . Selecting high profile journals ensures that the citation counts will tend to be high and the coverage of the journal will be large, both of which tend to maximise the statistical power of the analysis. The registry ClinicalTrials.gov was chosen despite the existence of many other registries internationally (Ogino et al. 2014) due to its large downloadable collection of about 216,000 clinical studies from the United States and 193 countries since 2000 (https://clinicaltrials.gov/ct2/resources/trends; 37 % were US-only trials in May 2016). Although published clinical trials tend to be more highly cited than average for the publishing journal (Romero et al. 2009 ), it is not known whether the same is true for articles cited by clinical trial records. The following two questions are addressed. A positive answer to the first question would give evidence that citations from ClinicalTrials.org are not random and also that they could be used for impact indicators (e.g., van Raan 1998), but would not demonstrate that they are unbiased or unaffected by selfcitations. This is therefore a first, but not final, step in validating clinical trials citation counts.
• Do articles in The BMJ, the New England Journal of Medicine, The Lancet and JAMA tend to attract more citations than average for the publishing journals when they are referenced in ClinicalTrials.gov records? • How does the answer to the above question vary over time?
Data and methods
Citations to journal articles in trials registered in ClinicalTrials.gov were identified by crawling all records in the site and extracting the cited references from the relevant sections of each document. The website permits crawling (https://www.clinicaltrials.gov/ robots.txt) and makes comprehensive crawling without duplication possible with a crawlerfriendly version of the site (https://www.clinicaltrials.gov/ct2/crawl). This was crawled by the free web crawler SocSciBot (socscibot.wlv.ac.uk) during April 19-24, 2016. A program was written to extract the cited publications (and other information) from each record. This is available in the free software Webometric Analyst (lexiurl.wlv.ac.uk: the ClinicalTrials.gov options in the Services and Citations menus).
Citations in trial records can be entered by the uploader or automatically inserted by ClinicalTrials.gov from trials that cite the study by its reference number. The automatically added citations are unlikely to have influenced the trials since they must have been published after the trial was registered in the site and hence all such citations were removed. The remaining citations are at the discretion of the uploader and may also refer to articles that publish the trial results, are influenced by the trial, or are otherwise related to the trial without influencing it. To reduce the possibility of these happening, only articles that had been published at least a year before the study start date were retained. Given normal publishing delays, these articles are likely to refer to research that was conducted at least 1-2 years prior to the start of the study and seem unlikely to be about the study rather than influencing it. This is a conservative approach given that articles publishing clinical trials results tend to appear about 2 years after the trial data collection has finished (Riveros et al. 2013) .
The citation counts of all regular articles in the four journals were extracted from Scopus using queries for the journal ISSN, the document type article, and each year from 2008 to 2016. Multiple ISSNs for a journal in Scopus (e.g., electronic and print) were searched separately. For example, one JAMA query was:
ISSN(1538-3598) AND DOCTYPE(ar) AND PUBYEAR IS 2015
The range 2008-2016 was chosen because 2008 was the first year in which the journal articles (almost) all had DOIs in Scopus.
Articles mentioned in ClinicalTrials.gov records can be referenced in many different formats and with many different variants of journal names. To ensure that articles referenced in trials records were correctly matched to their Scopus record, the matching process used article DOIs, when present. The remaining articles were matched by journal name (standardised across common variants), publication year and title (converted to lower case). Most articles contained DOIs and so this was the dominant matching mechanism. Articles referenced in trials that were not matched to a Scopus record despite having been published in one of the journals and years covered were ignored. These were predominantly non-article types of document (e.g., editorials, errata, images, comments, letters).
For each year, the average citation counts of articles referenced in ClinicalTrials.gov were compared against the average citation counts of the remaining articles in the four journals examined. Individual years were analysed separately because older articles can be expected to have higher citation counts. Articles published early in the year have longer to be cited compared to articles published later in the year but this advantage seems unlikely to affect either of the two groups more than the other and so this factor was ignored. Although there is a statistical technique to deal with this issue, it does not allow effect sizes to be estimated ) and so it was not used. For each journal/year combination, citation averages were calculated using the geometric mean with a 1 offset because citation data is highly skewed and so the arithmetic mean is inappropriate (Fairclough and Thelwall 2015; Zitt 2012) . All citation counts were normalised by dividing by the geometric mean citation count for the journal and year of publication. This is an extension of the standard citation normalisation technique (Waltman et al. 2011a, b) . This also allows 95 % confidence intervals to be calculated for the (geometric) mean using the normal distribution formula both within individual years and across years.
Results
In each of the four journals, the average number of citations attracted by prior articles referenced in ClinicalTrials.gov records is substantially higher than the average number of citations attracted by other articles in the same journals (Table 1) . This supports the hypothesis that citation by a clinical trial record is evidence of the likelihood of an article having above average impact, at least for its publishing journal (RQ1). The temporal trend in results varies by publishing journal (Figs. 1, 2 , 3, 4; see Table 2 for sample sizes). The BMJ and JAMA results are broadly consistent with no changes over time, whereas the results from The Lancet suggest lower evidence of impact for more recently published articles and the NEJM results are consistent with both. The current year (2016) is missing from the graphs because no trial recording a future start date (2017 or later) cited articles from any of the four journals published in 2016. Overall, then, the data does not give strong evidence of a substantial time lag between being referenced in a clinical trials record and becoming highly cited (RQ2).
Because all citation counts are normalised by dividing by the journal geometric mean, only the relative size difference between the two sets is important. For example, the graphs mask (as irrelevant for this paper) the fact that NEJM is more highly cited than The BMJ.
Discussion and conclusions
An important limitation is that ClinicalTrials.gov is a US-based site and therefore its citations can be expected to have a bias towards the US, as is the case with journal citations (Lancho-Barrantes et al. 2012) . The methodological restriction to a small number of high impact journals is another important limitation because these account for a small minority of medical articles and it is not clear that the patterns found in them would extend to the generality of medical research. For example, a high proportion of publications in high impact journals about a new topic is a statistically significant indirect indicator of a drug eventually being marketed (Kissin 2010) . Another weak point is that citation counts do not (Akcan et al. 2013 ) and so citation-based metrics may not be useful indicators for trial-related publications. Finally, citations from clinical trials records may be biased in some way, may have a high proportion of selfcitations, may disproportionately cite high impact types of documents (e.g., randomized control trials, systematic reviews or meta analyses) rather than primary research. Moreover, papers may also be more referenced by clinical trials if they have many authors or more funding, which may also affect their Scopus citation counts (e.g., Glänzel and Schubert 2001) . Thus, a more detailed analysis of the individual citations would be needed to validate the use of clinical trials citations for evaluation purposes.
The results give strong statistical evidence that articles from four leading medical journals that are cited with DOIs in ClinicalTrials.gov have higher citation counts than typical articles from the journal, at least for those that are 2-6 years old, depending on the journal, with the difference probably being due to statistical power differences rather than 8  430  44  154  37  581  71  370   2009  25  350  51  171  25  572  64  394   2010  31  339  42  176  18  431  61  375   2011  22  326  35  174  18  279  60  365   2012  28  494  38  211  10  252  52  398   2013  15  577  41  213  6  241  39  392   2014  14  661  37  225  4  232  24  389   2015  5  624  26  196  2  304  22  350   2016  1  110  4  55  2  94  8  80   All  149  3911  318  1575  122  2986  401  3113 Scientometrics (2016) 109:1341-1351 1347 journal differences. There are at least four potential reasons for the higher citation impact found.
• Articles referenced in ClinicalTrials.gov lead to medical or health care innovations by motivating (at least in part) the trials, and this value leads to them being more recognised and cited (including in articles derived from the trials).
• Articles referenced in ClinicalTrials.gov do not lead to medical or health care innovations but become more cited due to (a) being cited in articles derived from unsuccessful trials and/or (b) publicity due to the presence of the citation in the trial reference list.
• Articles referenced in ClinicalTrials.gov are disproportionately often self-citations from the clinical trials scientists, who tend to be highly cited successful researchers because they attract funding for clinical trials.
• Older articles referenced in ClinicalTrials.gov are selected because of their high citation counts, either directly (as prestigious articles) or indirectly (due to ranking boosts in digital library search engines or because their high contribution to research has already been recognised and led to high citations).
• Articles referenced in ClinicalTrials.gov tend to be highly cited types of articles, such as randomised control trials, systematic reviews or meta-analyses.
Citation in ClinicalTrials.gov would be most useful as an alternative impact indicator in the first case only because in the third and fourth cases, the indicator would tend to confirm what other indicators would show and in the second case the citation does not reflect a valuable contribution of the cited research. The higher citation impact is in addition to the more direct impact that articles can have on health outcomes through supporting or motivating clinical trials. The temporal results were inconclusive but do not give strong evidence for the value of using citation in a clinical trial record as evidence of likely future higher citation impact. Logically, however, the opposite is almost certainly true. Although articles published in the same year as the start of a trial were excluded for methodological reasons, when they are not derived from a trial then it would be valid to count contemporary trial citations to them. Thus, it would be possible to use citations from trials in the current year as evidence of likely future impact in practice. Such articles would probably have low numbers of journal article citations due to their newness and so the trial citation would be a valuable impact indicator.
A practical application of the findings is that researchers can use the presence of citations to their work in clinical trials records to support a claim for its potential long-term impact. Such citations can be found easily by searching the site using their last name (e.g., Google site:clinicaltrials.gov/ct2/show/ Whooley) or the titles of their articles (e.g., Google site:clinicaltrials.gov/ct2/show/ ''Prevalence of symptomatic pelvic floor disorders in US women''), and manually checking for correct matches. Given the possibility of irrelevant citations, as discussed above, authors might accompany such claims by brief contextual justification of the value of the cited research to the study (e.g., ''informed study methods''). From a wider research policy perspective, the potential of researchers to use evidence of citations from clinical trials as an indicator of likely future impact may provide a mild incentive to them to encourage the translation of their ideas into practice, which would presumably be a public good.
Appendix: Specific method details
The free web crawler SocSciBot (http://socscibot.wlv.ac.uk) crawled the ClinicalTrials.gov index site at https://www.clinicaltrials.gov/ct2/crawl) and the link files in the SocSciBot link results folder imported into Excel and used to extract a complete list of URLs. From these URLs, a complete list of standard study URLs was generated. A second SocSciBot crawl was then started, using a 1-s pause between requests (for politeness) and using a dummy fake startup URL and the above list of URLs as the start.txt initial list (this ensures that only URLs in the list are crawled).
When the crawl had finished, the free Webometric Analyst software (http://lexiurl.wlv. ac.uk) was used to extract the relevant information as follows.
• The Services menu, ClinicalTrials.gov: Extract information from SocSciBot crawl (e.g., AgesEligible, MeshTerms, Publications, PubsLinkedViaNCT) menu item was used to extract relevant information from the crawled pages (pointing the program to the root folder for the second crawl). ) Record list file.
• The Services menu, ClinicalTrials.gov: Summarise results of the above (e.g., study type, gender by year: pubs; keyword freqs.) menu item was used to generate summary information (pointing the program to the record list file generated above). ) Summary tables files.
• The Citation menu, Clinicaltrials.gov (or similar): Extract citations from |-separated col, extract doi and year, match with record year menu item was used to generate lists of users-added publications (pointing the program to the record list file generated above, and selecting the user-added publications column). ) List of user added publications file.
• Using Scopus, a list of all publications of type journal article was extracted for JAMA, BMJ, Lancet and NEJM. ) Scopus articles file.
• The Scopus publication list was matched with each of the above two publications files by exact doi matching (case insensitive) or, for articles without DOI matches, title, journal name and year matching (case insensitive) using the Citation menu, Match DOIs or article title, year, journal from one file with same info from another menu item (selecting the Scopus articles file first, then the List of user added publications file). ) List of user added publications and matching Scopus records file.
• Duplicate user added publication matches (i.e., the same publication cited by different trials records) were removed in Excel. Publications from the same or later year than the trial start year were also removed in Excel. ) List of unique user added prior publications and matching Scopus records file.
• Geometric mean normalised citation counts for each file were created using the Citation menu, Calculate geometric mean normalised citation counts for a marked subset of articles, separately by year menu item (selecting the Scopus articles file first, then the List of user added publications file). ) geometric mean normalised user added results file.
